Document:

<PAGE>

                                                                    EXHIBIT 10.1

                              EMPLOYMENT AGREEMENT

        This EMPLOYMENT AGREEMENT is made as of March 3, 2003, by and between
Senetek PLC, a company organized under the laws of England (the "Company"), and
Mr. Brad Holsworth (the "Employee"), with reference to the following facts:

                                    RECITALS:

        The Company has retained the Employee as a consultant, and now desires
to employ the Employee as the Company's Chief Financial Officer, and the
Employee desires to be so employed by the Company. In consideration of the
foregoing recitals and the mutual covenants herein set forth, the parties agree
as follows:

        1. Employment; Acceptance: The Company hereby employs the Employee and
the Employee hereby accepts employment by the Company as the Company's Chief
Financial Officer or in such other capacity consistent with the Employee's
experience and competencies and of a level at least comparable to the position
specified above as may be assigned to the Employee by the Chief Executive
Officer of the Company.

        2. Duties and Powers: The Employee agrees to devote his full business
time, attention, energies and abilities to the proper management and conduct of
the Company's business, provided that, subject to Section 7.3, the Employee may
serve on the Board of Directors, advisory committee, or the like of not more
than two for-profit or not-for-profit business organizations at any one time
during the Term, provided, further, that such service does not interfere with or
detract from the Employee's services on behalf of the Company. The Employee
shall have full power and authority, subject to the By-laws of the Company and
the direction of the Chief Executive Officer and the Board of Directors of the
Company (the "Board"), generally to manage, administer and conduct the business
and affairs of the

<PAGE>

Company within the Employee's area of responsibility, and shall have such other
duties, powers and authority as are prescribed by the Chief Executive Officer,
the By-laws of the Company and the Board.

        3. Term: The employment of the Employee by the Company pursuant to this
Agreement shall commence on March 3, 2003 and continue until April 30, 2005,
unless the Employee's employment is sooner terminated in accordance with Section
5 or 6.

        4. Compensation: The Company hereby agrees to pay to the Employee an
annual salary of $185,000. Such salary shall be payable in installments
according to the Company's regular payroll practice, subject to withholding and
social security, unemployment and other taxes; provided that if the Employee's
employment terminates on any date other than on the last day of a calendar
month, then the compensation payable pursuant to this Section 4 for the monthly
period during which the period of employment has been terminated shall be
prorated.

        5. Other Benefits:

        5.1     Management Bonus Plan. Commencing with calendar year 2003, the
Employee shall be eligible to participate in a Management Bonus Plan developed
and administered by the Compensation Committee of the Board pursuant to which,
for each calendar year, participants may earn, based on individual performance,
up to a percentage of the participant's salary or other amount established at
the beginning of the year, payable from a bonus fund measured by the Company's
performance during the year. For 2003, the Compensation Committee has approved a
formula under which the bonus fund shall be equal to ten (10) percent of the
amount by which operating income for the year exceeds fifteen (15) percent of
revenues, such bonus to be payable in cash and/or shares of the Company's stock,
all as determined by the Compensation Committee. In recognition of the
Employee's services as a consultant, the Employee's bonus for 2003 shall be
calculated as if the Employee had commenced service effective January 1, 2003,
and shall not be prorated.

        5.2     Vacation: The Employee shall be entitled to take an annual
vacation in

<PAGE>

accordance with the policy of the Company with respect thereto. The Company
policy is three weeks of paid vacation during each complete 12-month period of
employment. For 2003, the Company agrees that the Employee may take one week of
vacation at the end of June and another week toward the end of July, to
accommodate scheduled family events, plus one day in mid-March.

        5.3     Expenses: The Company shall reimburse the Employee for
reasonable travel, entertainment and other business expenses incurred in
connection with the performance of his duties hereunder (including business use
of a cell phone, attendance at professional seminars with prior approval and
reasonable business periodical subscriptions), in accordance with the policy of
the Company with respect thereto.

        5.4     Employee Benefit Plans: The Employee shall be entitled to
participate, on the same terms as other employees of the Company of the
Employee's level, in any medical, dental or other health plan, pension plan,
profit-sharing plan, and life or disability insurance plan that the Company may
from time to time adopt or maintain, any of which may be changed, terminated or
eliminated by the Company at any time in its exclusive discretion.

        5.5     Car Allowance: Employee shall be entitled to a car allowance in
the amount of $500 per month.

        5.5     Stock Options: Management shall recommend to the Compensation
Committee of the Board that within 15 days after the date hereof Employee be
granted non-qualified stock options to purchase 175,000 American Depositary
Shares representing Common Stock of the Company at an exercise price equal to
the market price of the American Depositary Shares on the date of grant and with
a four year vesting schedule, in accordance with the Company's Stock Option
Scheme 1. The Employee shall be considered by the Compensation Committee for
additional grants during the term of the Agreement.

<PAGE>

        6. Termination:

        6.1     By the Company for Cause: The Company may terminate this
Agreement and the Employee's employment for cause, effective immediately on the
day it gives notice of such termination to the Employee. "Cause" for this
purpose shall be defined as insobriety; conviction of a misdemeanor involving
moral turpitude or a felony; illegal business practices in connection with the
Company's business; misappropriation of the Company's assets; willful violation
of Company policies; excessive absence of the Employee from his employment
during usual working hours for reasons other than vacation, disability or
sickness; or any material breach by the Employee of any term or provision of
this Agreement. On such termination for cause, the Employee shall be entitled
only to his compensation hereunder to the date of such termination, and shall
not be entitled to any other compensation, including, without limitation, any
severance compensation.

        6.2     Disability: If the Employee becomes unable fully to perform the
Employee's duties hereunder because of legal disability (including an injunction
or similar order or decree of a court of competent jurisdiction preventing or
severely impairing the performance of his duties hereunder), the Company may
terminate this Agreement by written notice to Employee effective on the date
stated in the notice. In addition, except as otherwise required by applicable
law, if the Employee becomes unable fully to perform the Employee's duties
hereunder because of physical or mental injury or illness and such inability
continues for a period of six consecutive months or eight months in any twelve
month period, the Company may terminate this Agreement by written notice to the
Employee effective at the end of such six month or twelve month period, and the
Employee shall not be entitled to any compensation or other payment after the
effective date of such notice, provided, however, Employee shall be entitled to
disability benefits under any Company provided disability benefit plan.

        6.3     Death. In the event of the Employee's death during the term of
this Agreement, this Agreement shall automatically terminate on the date of
death, and the Employee's legal representative

<PAGE>

shall be entitled to receive payment of the Employee's compensation hereunder to
the date of the Employee's death, and shall not be entitled to any other
compensation or payment, provided, however, that Employee's designated
beneficiary shall be entitled to death benefits under any Company-provided life
insurance plan or program in which the Employee participated on the date of
death.

        6.4     Other Termination. The Company reserves the full right and
authority to terminate the Employee's employment otherwise than as provided in
Section 6.1, 6.2 or 6.3, for any reason or without reason. The Employee also
reserves the full right and authority to terminate the Employee's employment in
the event of a material breach by the Company of the terms of this Agreement,
provided that the Employee shall give the Company fifteen days' prior written
notice of such breach and the Company shall have the right to cure such breach
during such period, or in the event that the Compensation Committee of the Board
shall not grant stock options as recommended by management as provided in
Section 5.5. If the Company or the Employee so terminates the Employee's
employment, the Employee shall be entitled to receive (subject to compliance
with the terms of Section 7) continued payment of the Employee's compensation
under Section 4, at the rate in effect on the date of termination, for a period
of twelve months, in lieu of any and all other benefits provided under this
Agreement other than as provided in any benefit plans of the Company in which
the Employee then participates.

        6.5     Merger; Sale of Assets: This Agreement shall not be terminated
by any reorganization, merger or consolidation of the Company, any sale of all
of substantially all of the assets of the Company, or the adoption by the
stockholders of the Company of any plan relating to the liquidation or
dissolution of the Company in connection with any such other transaction
(collectively, a "Corporate Event"), if a surviving or resulting corporation or
other entity or person continues (or resumes after a period of not more than
sixty days) the business of the Company. In any such event, if the business of
the Company is so continued or so resumed, this Agreement shall be binding on
and

<PAGE>

shall inure to the benefit of the corporation or other entity or person
surviving or resulting or to which such assets shall have been transferred, and
the Employee shall be assigned duties with respect to that part or division of
such corporation or other entity or person that continues the business of the
Company that are as comparable as possible to the Employee's duties with respect
to the Company immediately prior to such transaction. If, in any such event, the
business of the Company is not so continued or so resumed, such event shall be
deemed to constitute termination pursuant to Section 6.4., except as otherwise
provided in Section 6.6.

        6.6     Hostile Change of Control. In the event of (a) any Corporate
Transaction following which those persons who were stockholders of the Company
immediately prior to such Corporate Transaction hold less than a majority of the
voting power of the surviving or resulting corporation or other legal entity, or
(b) any acquisition by any individual or group acting in concert of a
controlling bloc of the voting securities of the Company, or (c) any change in
the Board such that a majority of the members have served less than twelve
months and were not elected or nominated for election by a majority of members
who have served for at least twelve months, then unless any such event described
in clause (a), (b) or (c) was approved in advance by a majority of members of
the Board of Directors who have served for at least twelve months or were
elected or nominated for election by a majority of members of have served for at
least twelve months, if within twelve months after such event the Employee's
employment is terminated as provided in Section 6.4, then in lieu of the
severance provided for in Section 6.4, the Company shall pay to the Employee in
a lump sum an amount equal to the lesser of (i) three times the sum of the
Employee's total cash compensation (inclusive of bonus, if any) during the
calendar year of the Term in which the Employee received the highest total cash
compensation, or (ii) the maximum amount that could be paid to the Employee
without causing any payments made to the Employee with respect to such event to
constitute an "excess parachute payment" as such term is defined in Section
280G(b)(1) of the Internal Revenue Code or any successor provision thereof.

<PAGE>

        7. Trade Secrets, Patents, Competition, Etc.:

        7.1     Trade Secrets: The Employee acknowledges that as an officer and
employee of the Company he has had and will have access to and has and will
become acquainted with various trade secrets and other proprietary and
confidential information of the Company (the "Trade Secrets"), including,
without limitation, designs, equipment, devices, patterns, electronically
recordable data or concepts, computer programs, software and hardware, software
and hardware enhancements, modifications and improvements, secret inventions,
processes, compilations of information, books, papers, records and
specifications, names, buying habits and practices of customers or potential
customers of the Company, marketing methods, operating practices and related
data, names of vendors and suppliers, costs of materials, prices the Company
obtains or has obtained or at which it sells or has sold its products or
services, manufacturing and sales costs, lists or other written records used in
the Company's business, compensation paid to Company employees and consultants
and other terms of employment, all of which are owned by the Company and are
regularly used or contemplated to be used in the business of the Company.

        The Employee agrees that he will not at any time, whether during or
subsequent to the term of his employment by the Company, without the specific
written consent of the Company in the particular case, directly or indirectly
use, disclose or communicate to any person or entity any Trade Secrets, for any
purpose, except such Trade Secrets as have been publicly disclosed through no
act or omission of the Employee. The Employee further acknowledges and agrees
that this Section 7 prohibits and precludes any use of Trade Secrets by him or
by any person obtaining any Trade Secrets directly or indirectly from him in
competition with the Company.

        The Employee further agrees that all written materials, including
without limitation files, records, documents, drawings and specifications, and
all equipment and devices and all other items

<PAGE>

relating to the business of the Company, whether prepared by or with the
assistance of the Employee or otherwise coming into his possession, control or
knowledge, are and shall remain the exclusive property of the Company and shall
not be removed from the premises of the Company under any circumstances. On
termination of his employment with the Company for any reason, the Employee
agrees to deliver promptly to the Company all of the foregoing which are or have
been in his possession or under his control.

        7.2     Inventions, Designs and Patents: The Employee agrees that he
will promptly and fully inform and disclose to the Company all inventions,
designs, improvements and discoveries which he conceives, alone or together with
others, during the term of this Agreement which relate to the existing or
contemplated business of the Company ("Inventions"). All Inventions are and
shall remain the exclusive property of the Company. The Employee agrees to
assist the Company to obtain any and all patents, trademarks, service marks and
copyrights relating to Inventions and to execute all documents and do all things
necessary to obtain letters patent and trademark, service mark and copyright
registrations, to vest the Company with full and exclusive title to each
Invention, all as and to the extent the Company may request.

        Notwithstanding the foregoing provisions of this Section 7.2, this
Section 7.2 shall not apply to an Invention developed entirely on the Employee's
own time without using the Company's equipment, supplies, facilities, or trade
secret information except for those Inventions that result from any work
performed by the Employee for the Company. The Employee acknowledges that this
paragraph constitutes the notification contemplated by California Labor Code
section 2872.

        7.3     Competition and Solicitation: The Employee agrees that the
Employee will not at any time during employment by the Company directly or
indirectly own other than a passive investment interest in, or be connected as
an officer, employee, agent, independent contractor, consultant, partner,
shareholder or principal with, any corporation, partnership, proprietorship,
association, or other entity or

<PAGE>

person engaged in developing, producing, designing, providing, soliciting orders
for, selling, distributing or marketing products or services that directly or
indirectly compete with the Company's products, services or business.

        The Employee further agrees that the Employee will not at any time
during employment by the Company and for a period of one year following
termination (voluntary or involuntary, whether or not for cause) of the
Employee's employment with the Company, directly or indirectly, and whether or
not for compensation, interfere with the business of the Company in any manner,
including, without limitation, (a) by diverting or attempting to divert from the
Company any business in which the Company is engaged or contemplates engaging,
or (b) by inducing any employee of the Company to leave the Company's employ or
any consultant or other independent contractor for the Company to change or
terminate any relationship between that person and the Company.

        7.4     Injunctive Relief: The Employee acknowledges and agrees that
failure to perform any of the Employee's covenants in this Section 7 would cause
irreparable injury to the Company and cause damages to the Company which would
be difficult or impossible to quantify or redress with money damages.
Accordingly, without limiting any remedies that may be available with respect to
any breach of this Agreement, upon a showing by the Company of a breach or
threatened breach of this Section 7 by the Employee, the Employee consents to
the entry of an injunction to restrain any breach of this Section 7.

        7.5     Infringement. The Employee represents and warrants that the
Employee does not possess and will not knowingly use, in connection with the
Employee's employment by the Company, any trade secrets or other confidential or
proprietary information or intellectual property in which any other person has
any right, title or interest and that the Employee's employment by the Company
as contemplated hereby will not infringe or violate the rights of any other
corporation, partnership, firm, proprietorship, association or other person.

<PAGE>

        7.6.    Survival. The representations, warranties and agreements in this
Section 7 shall survive any cancellation, termination, rescission or expiration
of this Agreement and any termination of the Employee's employment with the
Company.

        8. Severability. The invalidity or unenforceability of any provision
hereof shall in no way affect the validity or enforceability of any other
provision hereof.

        9. Notices. Except as otherwise specifically provided herein, any
notice, consent, demand or other communication to be given under or in
connection with this Agreement shall be in writing and shall be deemed duly
given on the date delivered personally or transmitted by facsimile transmission,
or one day after being deposited with Federal Express or other nationally
recognized delivery service for overnight delivery, or three days after being
mailed by first class mail, charges or postage prepaid, properly addressed, if
to the Company, at its principal office, and, if to the Employee, at his address
set forth following his signature below. Either party may change such address
from time to time by notice to the other.

        10. Governing Law. This Agreement shall be governed by and construed and
interpreted in accordance with the laws of the State of California.

        11. Assignment. Except as otherwise specifically provided herein,
neither party shall assign this Agreement or any rights hereunder without the
consent of the other party, and any attempted or purported assignment without
such consent shall be void; provided that the Employee's consent shall not be
required hereby for any of the transactions to which section 6.5 hereof refers.
This Agreement shall otherwise bind and inure to the benefit of the parties
hereto and their respective successors, assigns, heirs, legatees, devisees,
executors, administrators and legal representatives.

        12. Entire Agreement. This Agreement contains the entire agreement of
the parties and supersedes all prior or contemporaneous negotiations,
correspondence. understandings and agreements between the parties regarding the
subject matter of this Agreement. This Agreement may not be

<PAGE>

amended or modified except in writing signed by both parties and supported by
new consideration.

        IN WITNESS WHEREOF, this Agreement has been duly executed by or on
behalf of the parties hereto as of the date first above written.

                                            Senetek PLC

                                            By:
-----------------------------                  -----------------------------

Brad Holsworth                                    Frank J. Massino

                                                  Chairman & CEO

--------------------

--------------------<PAGE>

                                                                    EXHIBIT 10.2

                             DISTRIBUTION AGREEMENT

                                 By and Between

                                   SENETEKPLC

                                       and

                                 LAVIPHARM S.A.

                           Dated as of March 21, 2003

(***) CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

                                                                               1

<PAGE>

                             DISTRIBUTION AGREEMENT

        This agreement ("Agreement") is made and entered into as of March 21,
2003, by and between Senetek Plc, a United Kingdom corporation ("SENETEK"), and
Lavipharm S.A., a Greek corporation ("LAVIPHARM").

        SENETEK holds certain patents for Kinetin, including the right to
manufacture, have manufactured and sell products containing Kinetin. LAVIPHARM
desires to market and sell in the ethical market channel specific formulations
containing Kinetin for use as a skin care product. SENETEK is willing to grant
LAVIPHARM the exclusive right to market and sell such formulations subject to
the terms and conditions of this Agreement.

        Accordingly, in consideration of the mutual promises, covenants, and
conditions set forth below, the parties agree as follows:

                                 1. DEFINITIONS

        1.1     When used in this Agreement, each of the following capitalized
terms shall have the respective meaning set forth in this Article.

        1.2     "Affiliate" means, with respect to any Person, another Person
                controlled by, controlling or under common control with such
                Person.

        1.3     "Authorized Channel" means the sale of the products in the
                ethical market channel (pharmacy outlet) for use by patients
                under the care and supervision of physicians and/or
                dermatologists.

        1.4     "Base Price" means the price per 55 gallon drum of the products
                during the first Contract Year as set forth on Exhibit F and as
                thereafter adjusted pursuant to Section 3.3.3 for subsequent
                Contract Years and, during any period that LAVIPHARM elects to
                manufacture Products as provided in Section 2.2 or 4.5, means
                the price per kilogram of Kinetin active ingredient during the
                first Contract Year as set forth on Exhibit F and as thereafter
                adjusted pursuant to Section 3.3.3.

        1.5     "Best Efforts" means that commercially reasonable degree of
                effort, expertise, knowledge and resources which one skilled,
                able, familiar with and experienced in the matters set forth
                herein would utilize and otherwise apply with respect to
                fulfilling an obligation.

        1.6     "SENETEK Confidential Information" means the Know-How,
                non-public information concerning the Patents, Improvements,
                marketing, sales, financial, scientific, and other non-public
                and/or proprietary information concerning the products,
                projects, business and operations of SENETEK disclosed by
                SENETEK to LAVIPHARM.

        1.7     "Calendar Quarter" means a period beginning on the first day of
                January, April, July or October and ending on the last day of
                March, June, September, or December, respectively.

                                                                               2

<PAGE>

        1.8     "Contract Year" means a period beginning on first day of a
                calendar year and ending on the last day of such calendar year,
                provided, that the first Contract Year shall be the period
                beginning on the date of this Agreement and ending on December
                31, 2004 and the last Contract Year shall be the period ending
                on the date of termination of this Agreement.

        1.9     " Disruption Period" means any period during which SENETEK is
                unable to deliver the Products to LAVIPHARM and has notified
                LAVIPHARM at least thirty (30) days in advance.

        1.10    "Improvement" means any information, discovery, creation,
                derivative work, invention, or trade secret, whether or not
                patented or patentable or copyrighted or copyrightable, that
                relates to or is based upon the Patents or Know-How and is
                developed or otherwise acquired by either party or its
                respective affiliates.

        1.11    "Know-How" means such know-how, special knowledge, technical or
                other information, whether or not patented or patentable, owned
                or controlled by SENETEK or its Affiliates at any time prior to
                or during the term of this Agreement specifically related to the
                development, manufacture or use of any Product.

        1.12    "LAVIPHARM Confidential Information" means marketing, sales,
                financial, scientific, and other non-public and/or proprietary
                information concerning the products, projects, business and
                operations of LAVIPHARM including the manufacture, use, or sale
                of the Products disclosed by LAVIPHARM to SENETEK.

        1.13    "Net Sales" as used herein means the gross amount billed for
                commercial sales of the Products sold, or otherwise distributed
                to any party by LAVIPHARM, its Affiliates or its sub-licensees
                or distributors (not including sales by LAVIPHARM to its
                Affiliates or sub- licensees or distributors), less the
                following deductions:

                        (a) trade, quantity, or cash discounts, applicable to
                        gross amounts billed and allowed, paid or otherwise
                        included in determining net sales in accordance with
                        generally accepted accounting principles applied by
                        LAVIPHARM in preparing its audited financial statements
                        consistently from period to period ("GAAP");

                        (b) credit or allowance, if any, given or made on
                        account of a reasonable number of returns (supported by
                        appropriate documentation) of Products previously
                        delivered.

        1.14    "Patents" means the patents for Kinetin set forth on Exhibit A.

        1.15    "Person" means an individual, legal entity, government or agency
                thereof.

        1.16    "Product(s)" means the lotion formulation containing Kinetin as
                set forth in Exhibit B (the "Lotion"), the cream formulation
                containing Kinetin as set forth in exhibit C (the "Cream"), the
                SPF lotion formulation containing Kinetin as set forth in
                Exhibit D (the "SPF Lotion"), the eye product formulation
                containing Kinetin as set forth in Exhibit E (the "Eye
                Product"), and all line extensions and enhanced

                                                                               3

<PAGE>

                formulations of the foregoing, provided that during any period
                that LAVIPHAM is manufacturing Product pursuant to Section 2.2
                or 4.5, "Product" shall mean, for purposes of Sections 4.2
                through 4.4 hereof, the Kinetin active ingredient to be
                incorporated into Product.

        1.17    "Specifications" means the specifications for the Lotion set
                forth in Exhibit B, for the Cream set forth in Exhibit C, for
                the SPF Lotion set forth in Exhibit D, for the eye product set
                forth in Exhibit E, and for all line extensions and enhanced
                formulations of the foregoing.

        1.18    "Territory" means Greece and Cyprus.

        1.19    "Term" means the period starting on the date of this Agreement
                and ending upon the expiration of the last to expire of the
                Patents, unless this Agreement is sooner terminated in
                accordance with its terms.

        1.20    "Trademark" means LAVIPHARM's registered trademarks held by
                LAVIPHARM in the Territory used to designate the Product for its
                sale under the terms of the present Agreement.

        1.21    "Unit" means an individual unit of Products packaged by
                LAVIPHARM as specified by LAVIPHARM from time to time and
                acceptable to SENETEK.

                           2. GRANT OF RIGHTS TO SELL

        2.1     Supply. During the Term, SENETEK agrees to supply and deliver to
                LAVIPHARM, and LAVIPHARM agrees to purchase from SENETEK,
                Products in bulk in such quantities as LAVIPHARM requests. All
                orders for Product shall be made pursuant to written purchase
                orders and in accordance with the binding forecasts delivered to
                SENETEK in accordance with Section 4.3.

        2.2     Right to Manufacture. After 180 days from the date of the first
                delivery of bulk supply by SENETEK to LAVIPHARM, LAVIPHARM shall
                have an option to transfer the manufacturing process for the
                Products to a manufacturing site designated by LAVIPHARM;
                provided that the designated manufacturing site is qualified and
                acceptable to SENETEK and provided further that LAVIPHARM
                commits to purchase Kinetin from SENETEK as the sole supplier at
                a price equal to (***) per Kilogram (kg), subject to adjustment
                not more frequently than once per Contract Year to reflect
                increases in SENETEK's cost of goods, which adjustment shall be
                limited to the amounts by which third party invoices to SENETEK
                for manufacturing, packing and shipping kinetin have increased
                since the last annual adjustment, if any, and shall not include
                increases in Senetek's overheads.

        2.3     Grant. SENETEK hereby grants to LAVIPHARM during the Term hereof
                the exclusive right to package, market, distribute and sell the
                Products under the Trademark in the Authorized Channel within
                the Territory, and from an after such date as LAVIPHARM may
                exercise the option to transfer manufacturing of Products as
                provided in Section

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                               4

<PAGE>

                2.2 or 4.5, the exclusive right to manufacture the Products
                under the Trademark in the Territory, in each case subject to
                terms of this Agreement (the "Rights").

        2.4     Other Countries. Beginning ninety (90) days after the date of
                this Agreement, LAVIPHARM and SENETEK shall negotiate in good
                faith to reach agreement upon terms under which LAVIPHARM may
                sell the Products in the Authorized Channel in areas outside the
                Territory either directly or indirectly (e.g. through sub
                distributors with which SENETEK would not have direct
                cooperation,), provided that each party shall have full
                discretion in deciding whether, and upon what terms, it will
                agree to sales outside the Territory. SENETEK however
                acknowledges that LAVIPHARM is exporting its product lines under
                the Trademark to the countries/companies set forth in Exhibit H.
                Senetek agrees that the identities of such existing and any new
                proposed sub-distributors in other countries shall be deemed to
                be Confidential Information, not to be used by Senetek otherwise
                than for purposes of performing this Agreement.

        2.5     Exclusivity. With the exception of ICN Pharmaceuticals Inc.,
                SENETEK shall not grant any other party the right to sell the
                Products in the Authorized Channel in the Territory during the
                Term (the "Exclusivity Right'). The Exclusivity Right may be
                terminated by SENETEK upon notice given to LAVIPHARM if
                LAVIPHARM fails to meet any Minimum Purchase Requirement set
                forth in Section 3.2 or any Minimum Unit Sales Requirement set
                forth in Section 5.1.6, or fails to market the Products in
                Greece by the first Calendar Quarter of 2004 or fails to launch
                marketing and distribution efforts in Greece as set forth in
                Section 5.1.5.

        2.6     No Other Rights. It is expressly understood that this Agreement
                grants no rights to LAVIPHARM for the sale of the Products, or
                to the formulas therefore, or under the Patents except those
                express rights set forth in Sections 2.1 through 2.5. Without
                limiting the foregoing, it is understood and agreed that
                LAVIPHARM has no right pursuant to this Agreement to, and shall
                not, (i) sell or permit its customers to sell the Products
                outside the Authorized Channel within the Territory, or (ii)
                manufacture or have made other than by SENETEK any Products
                (other than pursuant to Sections 2.2 and 4.5 of this Agreement).
                Upon any termination of this Agreement, LAVIPHARM shall have no
                right of any kind with respect to the Products, Patents or any
                Improvements for which LAVIPHARM may receive a license other
                than the right to complete the sale of Products then lawfully in
                its possession subject to the payment of royalties pursuant to
                Section 3.3.2. Nothing in the foregoing sentence shall diminish
                LAVIPHARM's rights in the Trademark or any trademark or other
                intellectual property owned by LAVIPHARM and used in connection
                with the Products. SENETEK agrees not to contest LAVIPHARM's
                rights in the Trademark or to perform any act or omission
                adverse to those rights or that could, in any manner, tarnish,
                degrade, or disparage the Trademark or that reflect adversely on
                LAVIPHARM's business or reputation both during the Term and
                after the expiration or termination of this Agreement. SENETEK
                will cooperate fully and in good faith with LAVIPHARM, at
                LAVIPHARM'S request and expense, for the purpose of securing,
                preserving and protecting Lavipharm's rights in the Trademark.
                In particular, any goodwill and improved reputation generated by
                the promotion, distribution, and sale of the Products with the
                Trademark shall inure to the benefit of LAVIPHARM, provided that
                the foregoing shall not be deemed to give LAVIPHARM any rights
                to sell the Products, or

                                                                               5

<PAGE>

                to the formulas therefore, or under the Patents, except as set
                forth in the first sentence hereof.

                             3 PURCHASE COMMITMENTS

        3.1     Initial Order. By executing this Agreement, LAVIPHARM places a
                non- cancelable order for 55 gallons of the Lotion, 55 gallons
                of the Cream, 55 gallon of the SPF Lotion, and 55 gallon of the
                Eye Product (the "Initial Order").

        3.2             Minimum Purchase Requirements. During each Contract
                        Year, LAVIPHARM shall purchase not less than the number
                        of gallons set forth below (the "Minimum Purchase
                        Requirement"):

                        Contract Year       SKUs             Total Gallons
                        -------------       ----             -------------
                              1
                                            Lotion               (***)
                                            Cream                (***)
                                            SPF Lotion           (***)
                                            Eye Product          (***)
                            Total

                              2
                                            Lotion               (***)
                                            Cream                (***)
                                            SPF Lotion           (***)
                                            Eye Product          (***)
                            Total

                            3 - 7                              (each year)
                                            Lotion               (***)
                                            Cream                (***)
                                            SPF Lotion           (***)
                                            Eye Product          (***)
                            Total

                        remaining years                      to be agreed at
                                                             least nine (9)
                                                             months in advance
                                                             of the relevant
                                                             year.

        The Minimum Purchase Requirement may be met with any combination of
Products (including line extensions and/or additional formulations) purchased by
LAVIPHARM in bulk pursuant to this Agreement. In the event LAVIPHARM fails to
meet the Minimum Purchase Requirement, SENETEK shall have the right to terminate
the Exclusivity Right provided to LAVIPHARM pursuant to Section 2.5 above.
Notwithstanding the foregoing, effective during any period that LAVIPHARM is
manufacturing Products pursuant to Section 2.2 or 4.5, in lieu of the fore gong
quantities of Bulk the Minimum Purchase Requirement shall be that number of
kilograms of Kinetin active ingredient that, pursuant to the Specifications, are
required to manufacture the quantities of Bulk set forth above.

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                               6

<PAGE>

        3.3     Payment.

                        3.3.1 Base Price. With respect to the Initial Order,
                LAVIPHARM shall provide to SENETEK written delivery instructions
                from time to time, specifying the quantities of Bulk it wishes
                to be delivered, not less than ninety (90) days prior to the
                requested delivery date, and payment with respect to such Bulk
                shall be due on the date of delivery, F.O.B. SENETEK'S point of
                shipment, provided that LAVIPHARM shall in any event take
                delivery of the full Initial Order and make payment in full
                therefore not later than December 31, 2003. With respect to each
                subsequent order, SENETEK may send an invoice for the Base Price
                for Product ordered by LAVIPHARM at any time after shipment.
                LAVIPHARM shall pay SENETEK such amount within sixty (60) days
                of the date of such invoice. Late payments shall be subject to a
                monthly processing fee of nine tenth of one percent (0.9%) of
                the amount due or, if such amount is not permitted by law, the
                minimum amount permitted by law. Shipping charges shall be
                invoiced upon shipment and paid by LAVIPHARM as otherwise set
                forth in this Section 3.3.1.

                        3.3.2 Royalties. In further consideration of the grant
                of the rights under this Agreement, LAVIPHARM shall pay to
                SENETEK a royalty of (***) per Unit, but no less than (***)
                percent (***) of Net Sales from the Products. The royalty shall
                be paid by LAVIPHARM to SENETEK quarterly with respect to sales
                of the Products during each Calendar Quarter within thirty (30)
                days after the end of such Calendar Quarter. Each royalty
                payment shall be accompanied by a statement setting forth in
                reasonable detail the basis for the calculation of the royalty
                amount paid. LAVIPHARM shall permit SENETEK reasonable access to
                the data necessary to audit such calculation upon request from
                SENETEK provided that any such audit shall be conducted by
                independent auditors located in Greece or by the Greek office or
                affiliate of an international firm of independent auditors, as
                selected by SENETEK. Any such audit shall be commenced by
                SENETEK no later than two (2) year following the end of the
                relevant Contract Year, and no more than one such audit shall be
                conducted during any twelve (12) month period. SENETEK shall pay
                the costs of such independent audit unless the audit finds that
                LAVIPHARM's calculation of total Net Sales in any calendar year
                was understated by more than 5% from the calculations arrived at
                by the audit.

                        3.3.3 Adjustments to Base Price. At the end of the first
                Contract Year and at the end of each following Contract Year,
                the Base Price, as previously adjusted, shall be adjusted based
                on changes in actual costs during the just completed Contract
                Year subject to adjustment not more frequently than once per
                Contract Year to reflect increases in SENETEK's cost of goods,
                which adjustment shall be limited to the amounts by which third
                party invoices to SENETEK for manufacturing, packing and
                shipping kinetin have increased since the last annual
                adjustment, if any, and shall not include increases in SENETEK's
                overheads.

                     4 MANUFACTURE AND DELIVERY OF PRODUCTS

        4.1     Source. The Products shall be manufactured at a third party
                manufacturing facility to be designated by SENETEK promptly
                following agreement by the parties upon the

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                               7

<PAGE>

                Specifications, or at such other third party manufacturing
                facility as SENETEK may designate from time to time.

        4.2     Orders. Orders for Products in bulk shall be delivered to
                SENETEK at the following address:

        SENETEK PLC
        620 Airpark Road Napa, CA 94558
        Attention: Purchasing Department

        or at such other address as SENETEK may give LAVIPHARM at least thirty
(30) days prior written notice.

        4.3     Requirements Forecasts. LAVIPHARM shall provide SENETEK with a
                rolling twelve (12) month forecast of its requirements for
                Products under this Agreement to be updated quarterly, and
                delivered to SENETEK at least thirty (30) days in advance of the
                period forecasted. The first ninety (90) days of each forecast
                shall constitute a firm order that is not subject to
                cancellation by LAVIPHARM.

        4.4     Delivery. SENETEK shall use its best efforts to fulfill orders
                within ninety (90) days of he date they are confirmed by
                SENETEK. LAVIPHARM may not cancel any order after it is
                confirmed. SENETEK shall ship the Products F.O.B. its
                manufacturer's point of shipment from the place of manufacture
                to such location within the Territory as LAVIPHARM specifies in
                the Order. LAVIPHARM shall reimburse SENETEK for all reasonable
                costs of shipping, including without limitation reasonable costs
                of insurance. Such costs shall be reflected in invoices
                delivered pursuant to Section 3.3.1.

        4.5     Interim Manufacturing License. During any Disruption Period,
                LAVIPHARM or its designee shall have a non-exclusive license to
                use the Patents, Know-How and SENETEK Confidential Information
                to produce the Products (the "License"). All manufacturing of
                the Products pursuant to the License shall be completed in
                compliance with the specifications set forth in this Agreement
                for the Products. The License shall terminate upon the first to
                occur of (a) notice from SENETEK to LAVIPHARM that it is able to
                resume production or (b) termination of this Agreement.

           5 REPRESENTATIONS, WARRANTIES AND CERTAIN COVENANTS OF THE
                                     PARTIES

        5.1     Representations, Warranties and Covenants of LAVIPHARM.
                LAVIPHARM represents, warrants and covenants as follows:

                        5.1.1 Qualifications and Authorization. LAVIPHARM is a
                corporation duly formed, validly existing and in good standing
                in the state of Greece with full corporate power and authority
                to conduct its business as it is now conducted and to enter into
                and perform this Agreement. LAVIPHARM is duly licensed or
                qualified to do business and is in good standing in each
                jurisdiction in which its operations or ownership of assets in
                connection with this Agreement requires such licensing or
                qualification.

                                                                               8

<PAGE>

                        5.1.2 No Conflict or Violation. Neither the execution,
                delivery or performance of this Agreement, nor compliance by
                LAVIPHARM with any of the provisions hereof, will (i) violate or
                conflict with any provision of the Certificate of Incorporation
                or Bylaws of LAVIPHARM, (ii) violate, conflict with, or result
                in a breach of any provision of, or constitute a default (or an
                event which, with notice or lapse of time or both, would
                constitute a default) under, or result in the creation of any
                encumbrance upon any of LAVIPHARM's assets under, any of the
                terms, conditions or provisions of any material contract,
                indebtedness, note, bond, indenture, security or pledge
                agreement, commitment, license, lease, franchise, permit,
                agreement, or other instrument or obligation to which LAVIPHARM
                is a party, or (iii) violate any statute, rule, regulation,
                ordinance, code, order, judgment, ruling, writ, injunction,
                decree or award applicable to LAVIPHARM, except, in the case of
                each of clauses (i), (ii) and (iii) above, for such violations,
                conflicts, breaches, defaults or creations of encumbrances
                which, in the aggregate, would not have a material adverse
                affect on the business of LAVIPHARM or its ability to perform
                this Agreement.

                        5.1.3 Compliance with Laws. LAVIPHARM shall comply in
                all material respects with any law, regulation, ordinance,
                order, injunction, decree or requirement applicable in each
                country of manufacture or sale by LAVIPHARM to the marketing or
                sale of the Products or applicable to any manufacture,
                packaging, storage, shipment or handling of Products by its
                designated manufacturer pursuant to Section 2.2 or 4.5.

                        5.1.4 Products Standards. LAVIPHARM warrants that any
                Products manufactured by its designated manufacturer will be
                manufactured in accordance with the Specifications, and that
                such Products will conform in all respects to the Specifications
                when delivered to the shipper for shipment to LAVIPHARM. Unless
                otherwise expressly agreed by SENETEK, all Kinetin used in the
                manufacture of any such Products shall be sourced exclusively
                from SENETEK or its designated supplier.

                        5.1.5 Marketing Efforts. LAVIPHARM will promote and
                market the Products in a manner consistent with its efforts for
                other products and general industry practice and the promotion
                and marketing plan as attached as Exhibit G (the "Promotion
                Commitment").

                        5.1.6 Product Launch. LAVIPHARM will use its best
                efforts to begin marketing the product no later than the end of
                the third Calendar Quarter of 2003.

                        5.1.7 Minimum Unit Sales. LAVIPHARM shall achieve
                Product sales in the Territory during the first Contract Year of
                not less than (***) Units and during the second Contract Year of
                not less than (***) units For each subsequent Contract Year, the
                Minimum Unit Sales shall be a number of units equal to the sum
                of (i) the prior Contract Year's Minimum Unit Sales in the
                Territory plus (ii) fifty percent (50%) of the amount by which
                LAVIPHARM's actual Unit sales for such prior Contract Year
                exceeded such Minimum Unit Sales. LAVIPHARM shall be permitted
                (but shall not be obligated) to cure a failure to achieve
                Minimum Unit Sales for a particular Contract Year by making
                payment to SENETEK, within thirty (30) days after the end of
                such Contract Year, of the royalty that would have been due if
                LAVIPHARM had achieved

                *** Confidential portions of this material have been omitted and
                filed separately with the securities and Exchange Commission.

                                                                               9

<PAGE>

                such Minimum Unit Sales, provided that LAVIPHARM shall not be
                permitted to so cure its failure to achieve Minimum Unit Sales
                in two successive Contract Years.

                        5.1.8 Acknowledgement of SENETEK's Patents' Validity,
                Enforceability and Ownership. In consideration of the benefits
                of Sections 2.1 through 2.5, LAVIPHARM, for itself and its
                Affiliates, successors and permitted assigns and sub- licensees,
                irrevocably acknowledges, admits and concedes that (i) all
                rights, title and interest in the SENETEK Patents are owned by
                SENETEK and its Affiliates, (ii) all claims of the SENETEK
                Patents as well as all claims that are narrower in scope than
                the claims of the SENETEK Patents are valid and enforceable, and
                (iii) all claims of any patent that may issue from any
                application whose subject matter in whole or in part is entitled
                to the benefit of the filing date(s) of the SENETEK Patents
                (including, without limitation, continuations,
                continuations-in-part, divisional patents, reexaminations,
                renewals, extensions, reissues, and foreign counterparts) that
                are equal to or narrower in scope than the claims of the SENETEK
                Patents are valid and enforceable. LAVIPHARM, for itself and its
                Affiliates, successors and permitted assigns and sub- licensees,
                does also forever relinquish and waive all rights to dispute
                said ownership, validity and enforceability in any proceeding of
                any nature, covenants that it and they will not assert, either
                affirmatively or defensively, in any proceeding of any nature,
                any matter inconsistent with said ownership, validity and
                enforceability, agrees and acknowledges that the foregoing shall
                act as a complete defense and bar to any proceeding of any
                nature challenging such ownership, validity and enforceability
                or any of them, and consents to the entry of temporary and
                permanent injunctions to bar any breach or threatened breach of
                any of the foregoing, without the filing on behalf of SENETEK of
                any bond or other security.

        5.2     Representations and Warranties and Covenants of SENETEK. SENETEK
                represents, warrants and covenants as follows:

                        5.2.1 Qualifications and Authorization. SENETEK is a
                corporation duly formed, validly existing and in good standing
                in the laws of England with full corporate power and authority
                to conduct its business as it is now conducted and to enter into
                and perform this Agreement. SENETEK is duly licensed or
                qualified to do business and is in good standing in each
                jurisdiction in which its operations or ownership of assets in
                connection with this Agreement requires such licensing or
                qualification.

                        5.2.2 No Conflict or Violation. Neither the execution,
                delivery or performance of this Agreement, nor compliance by
                SENETEK with any of the provisions hereof, will (i) violate or
                conflict with any provision of the Certificate of Incorporation
                and Bylaws of SENETEK, (ii) violate, conflict with, or result in
                a breach of any provision of, or constitute a default (or an
                event which, with notice or lapse of time or both, would
                constitute a default) under, or result in a creation of any
                encumbrance upon any of SENETEK's assets under, any of the
                terms, conditions or provisions of any material contract,
                indebtedness, note, bond, indenture, security or pledge
                agreement, commitment, license, lease, franchise, permit,
                agreement, or other instrument or obligation to which SENETEK is
                a party, or (iii) violate any statute, rule, regulation,
                ordinance, code, order, judgment ruling, writ, injunction,
                decree or award applicable to SENETEK, except, in the case of
                each of clauses (i), (ii) and (iii) above, for such

                                                                              10

<PAGE>

                violations, conflicts, breaches, defaults or creations of
                encumbrances which, in the aggregate, would not have material
                adverse effect on the business of SENETEK or its ability to
                perform this agreement.

                        5.2.3 Products Standards. SENETEK warrants that the
                Products manufactured by its designated manufacturer will be
                manufactured in accordance with the Specifications, and that
                such Products will conform in all respects to the Specifications
                when delivered to the shipper for shipment to LAVIPHARM.

                        5.2.4 Compliance with Law. SENETEK shall comply in all
                material respects with any law, regulation, ordinance, order,
                injunction, decree or requirement applicable to the manufacture,
                packaging, storage, shipment and sale of the Products.

                        5.2.5 Patents. SENETEK owns the Patents. To the
                knowledge of SENETEK: (i) the Patents do not infringe upon the
                rights of any third party; and (ii) the Patents are valid. In
                the event SENETEK intends to file any additional patent
                applications with respect to the Products, SENETEK shall, to the
                extent possible do so without impairing its intellectual
                property rights or violating agreements with or intellectual
                property rights of others, furnish a draft of the proposed
                filing to LAVIPHARM for review and comments at least thirty (30)
                days in advance of filing. Any such draft shall be treated as
                SENETEK Confidential Information and shall not constitute an
                offer to sell any product to LAVIPHARM.

                        5.2.6 Survival. The representations and warranties made
                in this Agreement shall survive the termination of this
                Agreement for the longer of (a) the statute of limitations
                applicable to claims for the breach of such representation or
                warranty and (b) such other period as may be specified in this
                Agreement.

                  6 CONFIDENTIAL INFORMATION AND ANNOUNCEMENTS

        6.1     SENETEK Confidential Information. LAVIPHARM shall not (a) use
                SENETEK Confidential Information except to perform its
                obligations under this Agreement, or (b) disclose SENETEK
                Confidential Information to any Person (except to its employees
                and agents who reasonably require same for the purpose hereof
                and who are bound to LAVIPHARM by the same obligations as to
                confidentiality) without the express written permission of
                SENETEK, unless such disclosure is required by order of a court
                of competent jurisdiction.

        6.2     LAVIPHARM Confidential Information. SENETEK shall not (a) use
                LAVIPHARM Confidential Information except to perform its
                obligations under this Agreement, or (b) disclose LAVIPHARM
                Confidential Information to any Person (except to its employees
                and agents who reasonably require same for the purpose hereof
                and who are bound to SENETEK by the same obligations as to
                confidentiality) without the express written permission of
                LAVIPHARM, unless such disclosure is required by order of a
                court of competent jurisdiction.

        6.3     No License. The furnishing of Confidential Information by one
                party to the other shall not constitute any grant, option or
                license to the other under any patent or other rights now or
                hereafter held by the furnishing party.

                                                                              11

<PAGE>

        6.4     Announcements. The parties will issue an agreed upon press
                release upon the execution of this Agreement. Except for such
                release and except as may otherwise be required by law, neither
                party will disclose the terms of this Agreement to any other
                Person; provided, however, that each party may make such
                disclosure of the terms of this Agreement to its employees and
                agents as is necessary to permit such party to perform its
                obligations under this Agreement; provided further that any such
                employee or agent agrees to maintain the confidentiality of this
                Agreement. Except as may be required by law, neither party will
                disclose the results of any clinical studies or other technical
                data concerning the Products; provided, however, that each party
                may make such disclosures (or permit disclosures) to show that
                products including Kinetin are more effective than those that do
                not include Kinetin.

        6.5     Survival. The provisions of this Article 6 shall survive
                termination of this Agreement and continue for a period of five
                (5) years.

              7 INDEMNIFICATION, INSURANCE AND LIMITS ON LIABILITY

        7.1     Indemnification of SENETEK. LAVIPHARM shall defend, indemnify,
                and hold harmless SENETEK, its officers, agents, employees and
                affiliates from any loss, claim, action, damage, expense or
                liability (including defense costs and attorneys' fees)
                (collectively, "Claims") arising out of or related to a breach
                or alleged breach of any representation, warranty or covenant
                made by LAVIPHARM herein, or the manufacturing pursuant to
                Section 2.2 or 4.5, or handling, possession, marketing, sale or
                other use of the Products, except insofar as such claims are
                related to or arise from SENETEK's negligence or breach of this
                Agreement.

        7.2     Indemnification of LAVIPHARM. SENETEK shall defend, indemnify,
                and hold harmless LAVIPHARM, its officers, agents, employees and
                affiliates from any Claims arising out of or related to a breach
                or alleged breach of any representation, warranty, or covenant
                made by SENETEK herein, or SENETEK's manufacture or handling of
                the Products, except insofar as such claims are related to or
                arise from LAVIPHARM's negligence or breach of this Agreement.

        7.3     Insurance. LAVIPHARM shall maintain at its expense commercial
                general liability insurance in a principal amount of not less
                than the coverage generally maintained by companies of similar
                size in the industry, but in no event shall LAVIPHARM be
                required to maintain coverage in excess of one (1) million
                dollars per occurrence and ten (10) million dollars in the
                aggregate. Within thirty (30) calendar days after the date of
                this Agreement, LAVIPHARM shall furnish to SENETEK a certificate
                evidencing such insurance. SENETEK may elect not to ship any
                product until such insurance is in place and the certificate of
                coverage is provided, and may thereafter suspend shipment if it
                reasonably believes such insurance is not in place until
                LAVIPHARM provides SENETEK reasonable assurance that such
                coverage is in place without any gap in coverage during the Term
                and will be maintained as required by this Agreement.

        7.4     No Consequential Damages. EXCEPT FOR CLAIMS THAT INCLUDE
                CONSEQUENTIAL DAMAGES PAID TO PERSONS THAT ARE NOT

                                                                              12

<PAGE>

                AFFILIATES OF AN INDEMNIFIED PARTY, NEITHER PARTY SHALL BE
                LIABLE TO THE OTHER FOR CONSEQUENTIAL DAMAGES, LOST PROFITS,
                INJURY TO REPUTATION OR SIMILAR CLAIMS. EXCEPT FOR CLAIMS BY
                THIRD PARTIES ARISING FROM THE FAILURE OF THE PRODUCTS SUPPLIED
                BY SENETEK PURSUANT TO THIS AGREEMENT TO CONFORM TO THE
                SPECIFICATIONS AT THE TIME OF SHIPMENT, UNDER NO CIRCUMSTANCES
                SHALL SENETEK OR ITS AFFILIATES HAVE ANY LIABILITY ARISING FROM
                THIS AGREEMENT IN EXCESS OF THE HIGHEST AGGREGATE AMOUNT PAID AS
                BASE PRICE AND ROYALTIES OVER THE COURSE OF ANY TWO CONTRACT
                YEAR PERIOD.

                                    8 RECALLS

        8.1     Responsibility. In the event any Product(s) must be recalled
                from the channel of distribution by reason of failure to meet
                any requirements of law or otherwise, LAVIPHARM shall have the
                sole responsibility to effect the recall. SENETEK shall
                cooperate with LAVIPHARM in implementing any such recalls to the
                extent such cooperation is necessary to effect the recall,
                provided that LAVIPHARM advances SENETEK'S expenses therefore,
                except as provided in Section 8.2.

        8.2     Reimbursement of LAVIPHARM. In the event the recall results from
                or is caused by an act or omission of SENETEK for which it is
                required to indemnify LAVIPHARM pursuant to Section 7.2, SENETEK
                shall reimburse LAVIPHARM for any costs and/or expenses
                reasonably expended by LAVIPHARM as a consequence of the recall.
                Without limiting the general nature of the foregoing, SENETEK
                will provide replacement Products or raw material or Kinetin for
                recalled Products and for any Products that cannot be shipped
                due to the condition requiring the recall.

                             9 TERM AND TERMINATION

        9.1     Term. The term of this Agreement shall commence on the date of
                this Agreement and shall terminate on the date of termination in
                accordance herewith.

        9.2     Termination. Each party shall have the right to terminate this
                Agreement at any time upon written notice to the other in the
                event (i) the other party fails to perform any material
                obligation and such failure continues for a period of sixty (60)
                days after notice thereof with respect to a payment failure or,
                with respect to any other failure, such failure continues for a
                period of sixty (60) days after notice thereof, or (ii) the
                other party is declared insolvent or bankrupt by a court of
                competent jurisdiction, or a voluntary petition of bankruptcy is
                filed in any court of competent jurisdiction by the other party,
                or the other party makes or executes any assignment for the
                benefit of creditors, or (iii) LAVIPHARM fails to meet Minimum
                Purchase Requirement as set forth in Section 3.2 for two (2)
                successive Contract Years or fails to meet the Minimum Unit
                Sales as set forth in Section 5.1.7 for two (2) successive
                Contract Years (if LAVIPHARM did not exercise its right to cure
                the first Contract Year's failure) or for three (3) successive
                Contract Years (if LAVIPHARM did exercise its right to cure the
                first Contract Year's failure). In addition, LAVIPHARM may
                terminate this Agreement without cause (i) at any time after the
                end of the fifth Contract Year upon six (6) months' written
                notice to SENETEK or (ii) at any time upon nine (9) months'
                written

                                                                              13

<PAGE>

                notice to SENETEK in the event LAVIPHARM's total number of units
                sold of the Products do not achieve the following threshold:

                          Contract Year             Amount
                          -------------             ------
                                1                   (***)
                                2                   (***)
                                3                   (***)
                                4                   (***)
                                5                   (***)

                                10 MISCELLANEOUS

        10.1    Method of Payments. All payments due under this Agreement shall
                be paid in U.S. Dollars by a check drawn on a United States bank
                or by wire transfer of immediately available funds.

        10.2    No Joint Venture. It is not the intent of the parties hereto to
                form any partnership or joint venture. Each Party shall, in
                relation to its obligations hereunder, act as an independent
                contractor, and nothing in this Agreement shall be construed to
                give either party the power or authority to act for, bind or
                commit the other.

        10.3    Governing Law. This Agreement shall be governed by and
                interpreted in accordance with the laws of the United Kingdom
                (regardless of that or any other jurisdiction's choice of law
                principles). LAVIPHARM and SENETEK irrevocably submit to the
                jurisdiction of the United Kingdom courts for the adjudication
                of any disputes related to or arising out of this Agreement.

        10.4    No Assignment. Neither party to this Agreement may assign its
                rights or obligations under this Agreement without the prior
                written consent of the other party to this Agreement; provided,
                however, that either party may assign its rights to any
                affiliate company or a person that acquires substantially all of
                the assets of such party; provided further, that no such
                assignment shall relieve the assigning party of its obligations
                under this Agreement.

        10.5    Force Majeure. No party hereto shall be liable to any other in
                damages for, nor shall this Agreement be terminable by reason
                of, any delay or default in such party's performance hereunder
                if such delay or default is caused by conditions beyond such
                party's control including, but not limited to, acts of God,
                regulation or law or other action of any government or any
                agency thereof, war, insurrection, civil commotion, destruction
                of production facilities or materials by earthquake, fire, flood
                or storm, labor disturbances, epidemic, or failure of suppliers,
                public utilities or common carriers. Each party hereto agrees to
                promptly notify the other party of any event of force majeure
                under this Section 11.5 and to employ all reasonable efforts
                towards prompt resumption of its performance hereunder when
                possible if such performance is delayed or interrupted by reason
                of such event.

                ***Confidential portions of this material have been omitted and
                filed separately with the securities and Exchange Commission.

                                                                              14

<PAGE>

        10.6    Notices. Unless otherwise provided herein, any notice required
                or permitted to be given hereunder (a "Notice") shall be mailed
                by certified mail or generally recognized express courier
                service with signature required for delivery, postage prepaid,
                or delivered by hand to the party to whom such Notice is
                required or permitted to be given hereunder. If mailed, any such
                Notice shall be deemed to have been given as of the date of
                receipt, as evidenced by the date appearing on the delivery
                notice. If delivered by hand, any such Notice shall be deemed to
                have been given when received by the party or agent of such
                party to whom such Notice is given, as evidenced by written and
                dated receipt of the receiving party.

                        All Notices to LAVIPHARM shall be addressed as follows:

                        LAVIPHARM S.A.
                        Agias Marinas
                        190 02 Peania
                        Greece
                        Attn.: Mr Paris Yassis

                        All Notices to SENETEK shall be addressed as follows:

                        SENETEK PLC
                        620 Airpark Road
                        Napa, CA 94558

                Either party may change the address to which any Notice to it is
                to be addressed by notification to the other party as provided
                herein.

        10.7    Captions. The captions in this Agreement are solely for
                convenience of reference and shall not be used for purposes of
                interpreting or construing the provisions hereof.

        10.8    Severability. Should any part or provision of this Agreement be
                held unenforceable or in conflict with the applicable laws or
                regulations of any applicable jurisdiction, the invalid or
                unenforceable part or provision shall be replaced with a
                provision which accomplishes, to the extent possible, the
                original business purpose of such part or provision in a valid
                and enforceable manner, and the remainder of this Agreement
                shall remain binding upon the parties hereto.

        10.9    Waiver. No failure on the part of any party hereto to exercise,
                and no delay in exercising, any right, privilege or power
                hereunder shall operate as a waiver or relinquishment thereof;
                nor shall any single or partial exercise by any party hereto of
                any right, privilege or power hereunder preclude any other or
                further exercise thereof, or the exercise of any other right,
                privilege or power.

        10.10   Entire Agreement. This Agreement together with its Schedules and
                Exhibits constitute the entire agreement and understanding
                between the parties hereto with respect to the subject matter of
                this Agreement and shall supersede any prior agreements,
                negotiations, understandings, representations, statements and
                writings relating thereto.

                                                                              15

<PAGE>

                This Agreement may not be amended or modified except in a
                writing signed by a duly authorized officer of the party against
                whom enforcement of such amendment is sought.

        10.11   Counterparts. This Agreement may be executed in one or more
                counterparts by exchange of facsimile copies of signature pages,
                each of which will be deemed an original and all of which
                together will constitute one and the same instrument.

        10.12   Document Preparation. The parties acknowledge that this
                Agreement is a product of extensive negotiations and that no
                inference should be drawn regarding the preparation of this
                document.

        To evidence this Agreement, the parties have caused their duly
authorized representatives to execute this Agreement as of the date first
written above.

LAVIPHARM SA
By:  /s/
    -----------------------
Name: Tania Vranopoulos
      ---------------------
Title: Chief Operating Officer
       -----------------------

SENETEKPLC
By:  /s/
    -----------------------
Name: Andreas Tobler
      --------------
Title: COO & MD Europe
       ---------------

                                                                              16

<PAGE>

                                    EXHIBIT A

                                     PATENT

Country: Greece
Patent No: 0584068
Issue Date: 10/06/1999
Title: Method/Composition for Ameliorating Adverse Effects of Aging Expiry
 Date: 05/16/2011
Status: Granted

Country: Greece
Patent No: 0584062 Issue Date: 1/7/1998
Title: Method and Composition for Treating Hyperproliferative Skin Diseases
 Expiry Date: 05/16/2011
Status: Granted

                                                                              17

<PAGE>

                                    EXHIBIT B

                              LOTION SPECIFICATIONS

[to set forth Lotion formulation]

                                                                              18

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name: Lotion with 0.1% KINETIN (#MCLT2-119-2005)

        I.     General Description
               -------------------
               White viscous lotion

II.       Analytical Requirements
                 Property                Limits                  Test Method
          -----------------------        ------                  -----------
          A. Appearance                  White viscous lotion
                                         To Match Master
          B. Odor                        Characteristic
                                         To Match Master
          C. Color                       White to off white
                                         To Match Master
          D. pH                          5.0 - 6.0
          E. Viscosity @25(DEG)C,        5,000 - 25,000 cps
             LVT #3@12RPM
          F. Total Solids (%)            9.50 - 11.50%
          G. Specific Gravity            0.97 - 1.03

III. Chemical Requirements
           Parameter            Target      Limits             Test Method
     ----------------------     ------      ------             -----------
          A. KINETIN            0.10%       0.095 - 0.105%

IV.  Microbiological Requirements
               Property               Limits            Test Method
     ----------------------------     ------            -----------
          A. Mesophilic Aerobic       * 100
             Bacteria
          B. Yeast                    * 100
          C. Mold                     * 100
          D. Gram Negative            None Detected
             Bacteria

* MEANS LESS THAN

                                                                              19

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name:
Spec Ref.                                        Minimum Test Frequency
Paragraph         Property           Release             Retest           Audit
               APPEARANCE          3 PER LOT*

               ODOR                3 PER LOT*

               COLOR               3 PER LOT*

               pH 3                PER LOT*

               VISCOSITY           3 PER LOT*

               MESOPHILIC          3 PER LOT**
               AEROBIC BACTERIA

               YEAST               3 PER LOT**

               MOLD                3 PER LOT**

               GRAM NEGATIVE       3 PER LOT**
               BACTERIA

Special Instructions:
             MASTER SAMPLE TO BE RENEWED EVERY 12 MONTHS.

Sampling Plan:
             * SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             BATCH OR LOT AND TESTED SEPARATELY.

             ** SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             EACH PACKAGING/FILLING SHIFT AND MAY BE COMPOSITED.

                                                                              20

<PAGE>

Product:    Lotion with 0.1% KINETIN (MCLT2-119-2005)

<TABLE>
<CAPTION>
ITEM CODE   RAW MATERIAL                                            PERCENTAGE WEIGHT
---------   ------------                                            -----------------
<S>         <C>                                                        <C>
            Water                                                                (***)
            Stearyl Alcohol (Lanette 18; COGNIS)                                 (***)
            Glyceryl Stearate and PEG-100 Stearate                               (***)
                                       (Mazo1 165; BASF)
            Glycerin (Emery 917; HENKEL)                                         (***)
            Hybrid Safflower Oil (Lipovol SO; LIPO)                              (***)
            Phenoxyethanol (and) Methylparaben (and)                             (***)
            Ethylparaben (and) Propylparaben (and)
            Butylparaben (Sepicide HB; SEPPIC)
            Octyl Hydroxystearate(Norfox 171; Norman, Fox&Co)                    (***)
            Cetyl Alcohol                                                        (***)
                (Crodacol C-95; CRODA or Lanette 16NF; COGNIS)
            Dimethicone (FLUID 200, 350 cst. DOWCORNING)                         (***)
            Sodium Benzoate (VELSICOL)                                           (***)
            Phytosterol (Generol 122; HENKEL)                                    (***)
            Panthenol Liquid (50% soln; ROCHE)                                   (***)
            Carbomer (Carbopol 940; GOODRICH)                                    (***)
            Triethanolamine (OXYCHEM)                                            (***)
            Kinetin (SENETEK)                                                    (***)
            Sodium Hydroxide                                                     (***)
            Disodium EDTA (Dissolvine NA-2; AKZO NOBEL)                          (***)
            Tocopheryl Acetate (ROCHE)                                           (***)
            Aloe Barbadensis Gel                                                 (***)
                         (Aloe Vera Gel REG. 40X; TERRY LABS)
            Royal Jelly Extract (ACTIVE ORGANICS)                                (***)
            Chamomile Extract BG (BELL)                                          (***)
            Ascorbic Acid (ROCHE)                                                (***)
                                                                       TOTAL 100.0000
</TABLE>

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                              21

<PAGE>

                                    EXHIBIT C

                              CREAM SPECIFICATIONS

[To set forth cream formulation]

                                                                              22

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name: Cream with 0.1% KINETIN (#MCCR1-123-200S)

I.       General Description
         White to off white cream

II.      Analytical Requirements
                Property                      Limits                 Test Method
         -----------------------              ------                 -----------
         A. Appearance                        Cream
                                              To Match Master
         B. Odor                              Characteristic
                                              To Match Master
         C. Color                             White to off white
                                              To Match Master
         D. pH                                5.0 - 6.0
         E. Viscosity @25(DEG)C, LVT #T-E     200,000 - 320,000 cps
             @12RPM
         F. Total Solids(%)                   20.0 - 26.0%
         G. Specific Gravity                  0.97 - 1.03

III.     Chemical Requirements
           Parameter (target)                 Limits                 Test Method
         ---------------------                ------                 -----------
         A. KINETIN (target; 0.100%)          0.095 - 0.105%

IV.      Microbiological Requirements
                  Property                    Limits                 Test Method
         ----------------------------         ------                 -----------
         A. Mesophilic Aerobic Bacteria       * 100
         B. Yeast                             * 100
         C. Mold                              * 100
         D. Gram Negative Bacteria            None Detected

* MEANS LESS

                                                                              23

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name:
Spec Ref.                                        Minimum Test Frequency
Paragraph      Property            Release              Retest            Audit
               APPEARANCE          3 PER LOT*

               ODOR                3 PER LOT*

               COLOR               3 PER LOT*

               pH                  3 PER LOT*

               VISCOSITY           3 PER LOT*

               MESOPHILIC          3 PER LOT**
               AEROBIC BACTERIA

               YEAST               3 PER LOT**

               MOLD                3 PER LOT**

               GRAM NEGATIVE       3 PER LOT**
               BACTERIA

Special Instructions:

             MASTER SAMPLE TO BE RENEWED EVERY 12 MONTHS.

Sampling Plan:
             * SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE AND END OF
             BATCH OR LOT AND TESTED SEPARATELY.

             ** SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE AND END OF
             EACH PACKAGING/FILLING SHIFT AND MAY BE COMPOSITED.

                                                                              24

<PAGE>

Product: Cream with 0.1% KINETIN (#MCCRl-123-2005)

<TABLE>
<CAPTION>
ITEM CODE   RAW MATERIAL                                            PERCENTAGE WEIGHT
<S>         <C>                                                        <C>
            Water                                                                (***)
            Avocado Oil (LIPO; LIPOVOL A)                                        (***)
            Almond Oil (LIPO; LIPOVOL ALM)                                       (***)
            Glyceryl Stearate and PEG-I00 Stearate                               (***)
                                 (Mazol 165; BASF)
            Stearic Acid (Emersol132; COGNIS)                                    (***)
            Glycerin (Emery 917; HENKEL)                                         (***)
            Cetearyl Alcohol and Ceteareth 20                                    (***)
                                 (Cosmowax J; CRODA)
            Phenoxyethanol (and) Methylparaben (and)                             (***)
            Ethylparaben (and) Propylparaben (and)
            Butylparaben (Sepicide HB; SEPPIC)
            Sorbitan Monostearate (Span 60 NF; UNIQEMA)                          (***)
            Dimethicone (FLUID 200, 350 cst. DOW CORNING)                        (***)
            Titanium dioxide WD3328, USP,CTFA, Bacteria                          (***)
            controlled (Whittaker, Clark & Daniels)
            Sodium Benzoate (VELSICOL)                                           (***)
            Kinetin                                                              (***)
            PEG-14M (polyox WSR 205; AMERCHOL)                                   (***)
            Sodium Hydroxide                                                     (***)
            Disodium EDTA (Dissolvine NA-2; AKZO NOBEL)                          (***)
            Tocopheryl Acetate (ROCHE)                                           (***)
            Aloe Barbadensis Gel                                                 (***)
                          (ALOE VERA GEL REG. 4 OX; TERRY LABS)
            Royal Jelly Extract (Active Organics)                                (***)
            Chamomile extract BG (BELL)                                          (***)
            Ascorbic Acid (ROCHE)                                                (***)
                                                                       TOTAL 100.0000
</TABLE>

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                              25

<PAGE>

                                    EXHIBIT D

    SPF LOTION SPECIFICATIONS, AS OF MARCH 21ST, 2003, PENDING TO BE AMENDED
                         AND/OR FINALIZED UNTIL MAY 2003

[To set forth SPF Lotion forn1ulation]

                                                                              26

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product: SPF LOTION with 0.1% KINETIN (#MCSPF2-121-2005)

I.  General Description
    -------------------
           White lotion

II. Analytical Requirements
           Property                           Limits                 Test Method
    -----------------------                   ------                 -----------
         A. Appearance                        Viscous lotion
                                              To Match Master
         B. Odor                              Characteristic
                                              To Match Master
         C. Color                             White to off white
                                              To Match Master
         D. pH                                6.5 - 7.5
         E. Viscosity @25(DEG)C, LVT #T-E     10,000 - 35,000 cps
             @12RPM
         F. Total Solids (%)                  21.0 - 27.0%
         G. Specific Gravity                  0.97 - 1.03

II. Chemical Requirements
      Parameter (target)                      Limits                 Test Method
    -----------------------                   ------                 -----------
         A. KINETIN (target: 0.10%)           0.095 - 0.105%

IV. Microbiological Requirements
            Property                          Limits                 Test Method
    ----------------------------              ------                 -----------
         A. Mesophilic Aerobic Bacteria       * 100
         B. Yeast                             * 100
         C. Mold                              * 100
         D. Gram Negative Bacteria            None Detected

* MEANS LESS THAN

                                                                              27

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name:
Spec Ref.                                        Minimum Test Frequency
Paragraph      Property            Release              Retest            Audit
               APPEARANCE          3 PER LOT*
               ODOR                3 PER LOT*
               COLOR               3 PER LOT*
               pH                  3 PER LOT*
               VISCOSITY           3 PER LOT*
               MESOPHILIC          3 PER LOT**
               AEROBIC BACTERIA
               YEAST               3 PER LOT**
               MOLD                3 PER LOT**
               GRAM NEGATIVE       3 PER LOT**
               BACTERIA

Special Instructions:

             MASTER SAMPLE TO BE RENEWED EVERY 12 MONTHS.

Sampling Plan:

             * SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             BATCH OR LOT AND TESTED SEPARATELY.

             ** SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             EACH PACKAGING/FILLING SHIFT AND MAY BE COMPOSITED.

                                                                              28

<PAGE>

Product: SPF LOTION with O.1% KINETIN (#MCSPF2-121-2005)

<TABLE>
<CAPTION>
Item Code   Raw Material                                           Percentage Weight
---------   ------------                                           -----------------
<S>         <C>                                                              <C>
            Water                                                             (***)
            Octylmethoxycinnamate                                             (***)
            Octyl Palmitate (and) Titanium Dioxide (and)                      (***)
            Alumina (and) Polyhydroxystearic Acid (and) Silica
                TIOVEIL OF; UNIQEMA)
            Propylene Glycol                                                  (***)
            Phenylbenzimimidazole Sulfonic Acid                               (***)
                (EUSOLEX 232; RONA)
            Octylhydroxy Stearate (Norfox 171;NORMAN,FOX&CO)                  (***)
            Triethanolamine (OXYCHEM)                                         (***)
            Aluminum Starch Octenylsuccinate                                  (***)
                (Dry Flo-PC, National Starch)
            Phenoxyethanol (and) Methylparaben (and)                          (***)
            Ethylparaben (and) Propylparaben (and)
            Butylparaben (Sepicide HB; SEPPIC)
            Cyclomethicone (DC345; DC)                                        (***)
            Cetyl Dimethicone (ABIL WAX 9801; GOLSSCHMIDT)                    (***)
            Glyceryl Stearate and PEG-100 Stearate                            (***)
                (Mazol 165; BASF)
            Cetyl Alcohol (COGNIS/CRODA)                                      (***)
            Behenyl Dimethicone                                               (***)
                (ABIL WAX 2440; GOLDSCHMIDT)
            Carbomer (Carbopol ETD2001; GOODRICH)                             (***)
            Stearic Acid (Emersol 132; COGNIS)                                (***)
            PEG-20 Almond Glycerides (CROVOL A-40, CRODA)                     (***)
            Sodium Benzoate (VELSICOL)                                        (***)
            Acrylate/C10-30 Alkyl Acrylate Crosspolymer                       (***)
                (PEMULEN TR-2, BF GOODRICH)
            Xanthan Gum (Keltrol T; KELCO)                                    (***)
            Kinetin (SENETEK)                                                 (***)
            Sodium Hydroxide                                                  (***)
            Disodium EDTA (Dissolvine NA-2; AKZO NOBEL)                       (***)
            Panthenol Liquid (50%, ROCHE)                                     (***)
            Tocopheryl Acetate (ROCHE)                                        (***)
            Aloe Barbadensis Gel (ALOE VERA GEL REG. 40X;
                0.0100 TERRY LABS)
            Chamomile Extract BG (BELL)                                       (***)
            Ascorbic Acid (ROCHE)                                             (***)
</TABLE>

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                              29

<PAGE>

                                    EXHIBIT E

                           EYE PRODUCT SPECIFICATIONS

[To set forth Eye Product formulation]

                                                                              30

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name: EYE GEL with O.025% KINETIN (#MCEY4-127-2005)

I.       General Description
         -------------------
         Opaque viscous gel

II.      Analytical Requirements
                Property                Limits                  Test Method
         -----------------------        ------                  -----------
         A. Appearance                  Opaque viscous gel
                                        To Match Master
         B. Odor                        Characteristic
                                        To Match Master
         C. Color                       White opaque
                                        To Match Master
         D. pH                          6.5 - 7.5
         E. Viscosity @25(DEG)C,        10,000 -50,000 cps
            LVT #T-F @12RPM
         F. Total Solids (%)            0.7 - 1.3%
         G. Specific Gravity            .97 - 1.03

III.     Chemical Requirements
               Parameter                Target Limits           Test Method
         ---------------------          -------------           -----------
         A. KINETIN                     0.025% 0.020 - 0.030%

IV.      Microbiological Requirements
                  Property              Limits                  Test Method
         ----------------------------   ------                  -----------
         A. Mesophilic Aerobic          * 100
            Bacteria
         B. Yeast                       * 100
         C. Mold                        * 100
         D. Gram Negative Bacteria      None Detected

* MEANS LESS THAN

                                                                              31

<PAGE>

                              PRODUCT SPECIFICATION
                                                       Item Code:
                                                       Loc:
                                                       Ref:
                                                       Spec Date:
                                                       QCP Revision:

Product Name:
Spec Ref.                                        Minimum Test Frequency
Paragraph      Property            Release               Retest           Audit
               APPEARANCE          3 PER LOT*
               ODOR                3 PER LOT*
               COLOR               3 PER LOT*
               pH                  3 PER LOT*
               VISCOSITY           3 PER LOT*
               MESOPHILIC          3 PER LOT**
               AEROBIC BACTERIA

               YEAST               3 PER LOT**
               MOLD                3 PER LOT**
               GRAM NEGATIVE       3 PER LOT**
               BACTERIA

Special Instructions:

             MASTER SAMPLE TO BE RENEWED EVERY 12 MONTHS.

Sampling Plan:

             * SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             BATCH OR LOT AND TESTED SEPARATELY.

             ** SAMPLES TO BE SELECTED FROM THE BEGINNING, MIDDLE, AND END OF
             EACH PACKAGING/FILLING SHIFT AND MAY BE COMPOSITED.

                                                                              32

<PAGE>

Product: EYE GEL with 0.025% OR 0.01% KINETIN (#MCEY4-127-2005)

<TABLE>
<CAPTION>
ITEM CODE    RAW MATERIAL                                       PERCENTAGE WEIGHT
<S>          <C>                                                    <C>
             DEIONIZED WATER                                                (***)
             BIOPOLYSACCHARIDE GUM-1                                        (***)
                     FUCOGEL 1000PP; Solabia/Barnet)
             PROPYLENE GLYCOL                                               (***)
             HYALURONIC ACID & GLUCOSAMINOGLYCAN                            (***)
                     (ACTIGLIDE; ACTIVE ORGANICS)
             ACTIFIRM TS (ACTIVE ORGANICS)                                  (***)
             WITCH HAZEL DISTILLATE                                         (***)
             GINKOBILOBA EXTRCT BG (ACTIVE ORGANICS)                        (***)
             Phenoxyethanol (and) Methylparaben (and)                       (***)
             Ethylparaben (and) Propylparaben(and)
             Butylparaben (Sepicide HB; SEPPIC)
             CARBOMER (CARBOPOL ETD 2001; BF GOODRICH)                      (***)
             SODIUM HYDROXIDE 30% aqueous solution                          (***)
             CUCUMBER EXTRACT BG (BELL)                                     (***)
             OLETH-20 (AMEROXOL OE-20; AMERCOL)                             (***)
             DISODIUM EDTA (Dissolvine NA-2; AKZO NOBEL)                    (***)
             KINETIN (SENETEK)                                     (***) or (***)
             50%PANTHANOL (ROCHE)                                           (***)
             ALLANTOIN (BARNET)                                             (***)
             SODIUM PCA (AJIDEW N-50; AJINOMOTO)                            (***)
             TOCOPHEROL (COVIOX T-50;)                                      (***)
             ASCORBIC ACID (ROCHE)                                          (***)
                                                                    TOTAL 100.000
</TABLE>

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                              33

<PAGE>

                                    EXHIBIT F

                                   BASE PRICE

        (bulk Product per gallon ordered and shipped in 55 gallon drums)

Lotion                   US$ (***)
Cream                    US$ (***)
Eye Gel                  US$ (***)
SPF Lotion               US$ (***)

                         (Kinetin active per Kilogram)

1 kg Kinetin             US$ 1(***)

*** Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission.

                                                                              34

<PAGE>

                                    EXHIBIT G

                  LAVIPHARM MARKETING AND PROMOTION COMMITTMENT

                                                                              35

<PAGE>

                         MARKETING PLAN CASTALIA KINETIN
                             YEAR 1 OCT '03 -DEC '04

<TABLE>
<CAPTION>
            OBJECTIVE                                      ACTION PLAN                                        TIMING
-----------------------------------   ---------------------------------------------------------   -------------------------------
<S>                                   <C>                                                         <C>
Establishement to the market obtain   Launch a new line under the brand name CAST ALIA with 4     Presentation to the pharmacies
market share                          innovative references against the symptoms of photodamage               oct'03
                                      with a strong andioxidant ingredient Numb. 6
                                      furfuryladenine 0,1%

Dermatologist Detailing               * Full coverage of Derms                                    * Oct '03
                                      4 Medical reps / 4 times per year * Special visits to
Brand image building, gain hight        op.Leaders                                                * Oct '03
                                      * Mailing to Derms
prescription market share in Derms    * Professional press advertising / articles / PR *          * Oct '03
                                        Participation in 4 Dermatological congress(local,
                                        national)                                                 * Jan '03

                                      Presentation Material
                                      * Monography with full clinical data of kinetin             * Oct '03
                                      * Scientific sales folder                                   * Oct '03
                                      * Reminder technical leaflet                                * Oct '03
                                      * Samples of the 4 references                               * Oct '03
                                      * Trial doses of 2 references                               * Oct '03

Pharmacists                           * Year sell-out contracts                                   * Jan '04
                                      * Sellout animations                                        * Jan '04
                                      * Sampling 100000 mini tubes                                * Oct '03
                                      * Training seminars                                         * Jan '04
Multiplication effect of the          * Pharmacists sales folder
Medical pull
Create credibility and gain market
share in pharmacies

Consumers                             * New CASTALIA line, new packaging                          * Oct '03
                                      * Attractive visual                                         * Oct '03
                                      * Consumer leaflet                                          * Oct '03
Communication effect + increase       * P.O.P. material: counter display stands, show cards       * Jan '04
visibility / awareness                * Institutional image for windows (300 pharmacies)          * Jan '04
                                      * Press releases dossier                                    * Oct '03

</TABLE>

                                                                              36

<PAGE>

                                    EXHIBIT H

                              CASTALIA DISTRIBUTION

TERRITORY                                  COMPANY
1. CHINA                                   PROFEX
2. KOREA                                   BANDO NEWPHARM
3. TAIWAN                                  ORIENT EUROPHARMA Co, Ltd
4. POLAND                                  DERMALIA
5. LEBANON                                 SIDECO
6. SAUDI ARABIA                            MEDICOPHARM
7. U.A.E.                                  METROMED
8. CYPRUS                                  LAVIPHARM CYPRUS Ltd.

                                                                              37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]